Hansa Biopharma AB (publ) (STO:HNSA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Jul 21
Swedish (OMX) Biotech Industry Analysis
UpdatedJul 21, 2024
DataAggregated Company Financials
Companies64
- 7D1.6%
- 3M14.8%
- 1Y21.9%
- YTD0.6%
The Biotech industry is up 1.6% in the last week, with Vitrolife up 22%. In the last 12 months, the industry was up 22%. Earnings are forecast to grow by 43% annually.
Industry Valuation and Performance
Has the Swedish Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 21 Jul 2024 | SEK 204.8b | SEK 31.3b | -SEK 5,446,317,859.85 | 44.7x | -37.6x | 6.5x |
| Tue, 18 Jun 2024 | SEK 190.0b | SEK 30.6b | -SEK 5,515,176,071.08 | 37.8x | -34.5x | 6.2x |
| Thu, 16 May 2024 | SEK 196.0b | SEK 31.0b | -SEK 5,211,861,229.87 | 45.7x | -37.6x | 6.3x |
| Sat, 13 Apr 2024 | SEK 179.8b | SEK 29.8b | -SEK 5,280,103,573.23 | 64.9x | -34.1x | 6x |
| Mon, 11 Mar 2024 | SEK 191.0b | SEK 29.8b | -SEK 5,646,599,210.35 | 57.9x | -33.8x | 6.4x |
| Wed, 07 Feb 2024 | SEK 186.2b | SEK 28.8b | -SEK 5,298,721,422.63 | 63.9x | -35.1x | 6.5x |
| Fri, 05 Jan 2024 | SEK 184.0b | SEK 28.7b | -SEK 1,197,745,187.00 | 61.4x | -153.6x | 6.4x |
| Sun, 03 Dec 2023 | SEK 172.5b | SEK 28.7b | -SEK 1,200,476,458.00 | 57.5x | -143.7x | 6x |
| Tue, 31 Oct 2023 | SEK 156.6b | SEK 28.8b | -SEK 2,066,402,089.00 | 45.1x | -75.8x | 5.4x |
| Thu, 28 Sep 2023 | SEK 158.6b | SEK 27.4b | -SEK 2,017,185,031.00 | 49.7x | -78.6x | 5.8x |
| Sat, 26 Aug 2023 | SEK 157.3b | SEK 27.6b | -SEK 1,544,638,274.00 | 51.3x | -101.8x | 5.7x |
| Mon, 24 Jul 2023 | SEK 157.6b | SEK 27.5b | -SEK 1,533,673,744.00 | 58.6x | -102.8x | 5.7x |
| Wed, 21 Jun 2023 | SEK 167.1b | SEK 26.4b | -SEK 1,295,207,256.00 | 45.3x | -129.1x | 6.3x |
| Fri, 19 May 2023 | SEK 171.9b | SEK 26.3b | -SEK 1,379,370,325.00 | 45x | -124.6x | 6.5x |
| Sun, 16 Apr 2023 | SEK 175.9b | SEK 25.4b | -SEK 2,031,220,245.00 | 40.4x | -86.6x | 6.9x |
| Tue, 14 Mar 2023 | SEK 166.3b | SEK 25.4b | -SEK 2,020,529,182.00 | 38x | -82.3x | 6.5x |
| Thu, 09 Feb 2023 | SEK 177.6b | SEK 24.2b | -SEK 1,753,177,701.00 | 29.1x | -101.3x | 7.3x |
| Sat, 07 Jan 2023 | SEK 157.9b | SEK 23.8b | -SEK 1,843,261,584.00 | 31.9x | -85.7x | 6.6x |
| Mon, 05 Dec 2022 | SEK 163.0b | SEK 23.8b | -SEK 1,783,317,061.00 | 32.2x | -91.4x | 6.8x |
| Wed, 02 Nov 2022 | SEK 150.3b | SEK 23.9b | -SEK 3,207,318,105.00 | 32.7x | -46.9x | 6.3x |
| Fri, 30 Sep 2022 | SEK 154.6b | SEK 22.9b | -SEK 3,319,812,331.00 | 30.5x | -46.6x | 6.8x |
| Sun, 28 Aug 2022 | SEK 161.7b | SEK 22.9b | -SEK 3,355,586,604.00 | 34.9x | -48.2x | 7.1x |
| Tue, 26 Jul 2022 | SEK 167.7b | SEK 22.7b | -SEK 3,478,626,887.00 | 35.5x | -48.2x | 7.4x |
| Thu, 23 Jun 2022 | SEK 146.7b | SEK 21.4b | -SEK 3,519,685,528.00 | 32.4x | -41.7x | 6.8x |
| Sat, 21 May 2022 | SEK 154.2b | SEK 21.4b | -SEK 3,350,837,895.00 | 44.6x | -46x | 7.2x |
| Mon, 18 Apr 2022 | SEK 176.2b | SEK 19.7b | -SEK 3,200,759,994.00 | 52.8x | -55.1x | 9x |
| Wed, 16 Mar 2022 | SEK 156.9b | SEK 19.6b | -SEK 3,013,909,572.00 | 50.3x | -52x | 8x |
| Fri, 11 Feb 2022 | SEK 173.8b | SEK 19.1b | -SEK 2,338,078,099.00 | 50.9x | -74.3x | 9.1x |
| Sun, 09 Jan 2022 | SEK 186.0b | SEK 19.1b | -SEK 2,003,694,869.00 | 55.7x | -92.8x | 9.7x |
| Tue, 07 Dec 2021 | SEK 173.6b | SEK 19.0b | -SEK 1,986,571,765.00 | 53x | -87.4x | 9.1x |
| Thu, 04 Nov 2021 | SEK 200.4b | SEK 19.0b | -SEK 1,182,008,492.00 | 54.8x | -169.6x | 10.6x |
| Sat, 02 Oct 2021 | SEK 202.5b | SEK 18.1b | -SEK 1,339,324,385.00 | 42.7x | -151.2x | 11.2x |
| Mon, 30 Aug 2021 | SEK 204.6b | SEK 18.1b | -SEK 1,175,418,285.95 | 59.5x | -174.1x | 11.3x |
Price to Earnings Ratio
-163.8x
Current Industry PE
- Investors are pessimistic on the Swedish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 7.3x is higher than the industry's current PS ratio of 6.5x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 20% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Swedish Healthcare industry?
| SE Market | -1.84% | |
| Healthcare | 0.80% | |
| Biotech | 1.60% | |
| Biotech | 1.60% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| VITR Vitrolife | SEK 221.20 | 22.2% +SEK 5.4b | 31.7% | PS8.5x | |
| BONEX Bonesupport Holding | SEK 289.80 | 2.4% +SEK 446.9m | 104.5% | PE66x | |
| BINV BioInvent International | SEK 43.35 | 18.4% +SEK 444.2m | 150.6% | PS46.6x | |
| EGTX Egetis Therapeutics | SEK 6.16 | 13.7% +SEK 216.5m | 54.6% | PS28.7x | |
| PROB Probi | SEK 281.00 | 4.1% +SEK 125.3m | 50.3% | PE233.7x |
